Contrary Research

As the cost of launching satellites into space becomes ever cheaper, consulting firms, think tanks, and equity researchers alike have speculated that the industry is approaching launch commoditization...

In the last year, few industries have captured cultural, regulatory, and investor interest to the same degree as prediction markets. Platforms like Kalshi and Polymarket, which have millions of active...

For decades, developing treatments for rare diseases, which are medical conditions that affect fewer than 200K people at any given time, were viewed as one of the least attractive markets for...

In January 2026, the FDA cleared the first cell reprogramming therapeutic drug for human testing with the implicit goal of reversing aging. Specifically, the agency cleared ER-100, a therapy designed...